Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, <i>β</i>  -chemokines and IL-16 secretion in HIV-1 infection

Burton, Catherine; Hardy, Gareth; Sullivan, Ann; Nelson, M; Gazzard, Brian; Gotch, Frances; Imami, Nesrina

doi:10.1046/j.1365-2249.2002.01993.x

Cited by 10 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MCP-1 and possibly other chemoattractant proteins are thought to be the molecular signals that direct such infiltration. We measured plasma MCP-1 concentrations and, despite these individuals' being subject to multiple infections and inflammatory insults and receiving antiretroviral therapies that can induce further changes in MCP-1 levels, [23][24][25] we found an association between higher values of MCP-1 and atherosclerosis. This finding provides support for our hypothesis that MCP-1 may play a crucial role in atherogenesis.…”

Section: Discussionmentioning

confidence: 99%

“…20 Some HIV proteins can induce the overexpression of MCP-1, and the levels of this protein may be altered during the course of HIV progression. [23][24][25] This disease feature is exacerbated in carriers of the MCP-1 mutant allele. As such, the evidence to date suggests that HIV infection and atherosclerosis share pathways in their pathogenesis.…”

mentioning

confidence: 99%

“…10 Several studies implicate the MCP-1-CCR-2 axis in the clinical course of HIV infection as well as in atherosclerosis. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] The different levels of expression of MCP-1 between the 2518G allele and the 2518A allele may represent a mechanism that in adults provides partial protection from the infection. 11 Furthermore, CCR-2 is a natural co-receptor used by HIV to enter the CD4 lymphocytes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele

et al. 2004

View full text Add to dashboard Cite

Background— Patients infected with HIV present with premature atherosclerosis, and the 2 diseases share common pathogenic pathways. We investigated mutations in the monocyte chemoattractant protein-1 (MCP-1) and CCR-2 genes, which are known to control aspects of these pathways, to ascertain whether they are involved in atherogenesis in these patients. Methods and Results— We performed carotid and femoral artery ultrasonography to detect subclinical atherosclerosis in patients infected with HIV (n=183). MCP-1–2518G and CCR-2 64I polymorphisms were determined in the HIV group and in a population-based control group (n=348). We also determined MCP-1 circulating levels in the HIV group. The presence of MCP-1–2518G in the group of patients with subclinical atherosclerosis was significantly higher than in patients without atherosclerotic lesions (47.5% versus 18.2%, respectively; P <0.001). Furthermore, the patients with atherosclerotic lesions had higher MCP-1 plasma concentrations than did patients without lesions (74.15 [4.03] versus 57.81 [3.67] pg/mL, respectively; P =0.03). When adjusted for known cardiovascular risk factors, the MCP-1–2518G allele was associated with subclinical atherosclerosis (OR 5.72, 95% CI 1.74 to 18.80, P =0.004). Compared with measurements conducted ≈2.5 years earlier in a subset of 40 patients, intima-media thickness (IMT) in the carotid artery progressed at a mean rate of 0.06 mm/y more rapidly in patients bearing the MCP-1-mutated allele ( P =0.08). Conclusions— HIV-infected patients with the MCP-1–2518G allele have a 5-fold increased risk for atherosclerosis, as assessed by ultrasonography.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Some HIV proteins can accelerate the production of MCP-1, and production seems to vary with the clinical progression of HIV. 48,49 The 2518G allele of the MCP-1 gene results in a 5-fold increased risk for atherosclerosis in HIV infected patients. 50 Clearly, inflammation and inflammatory markers play a key role in HIV associated atherogenesis.…”

Section: Hiv: a Proatherogenic Virusmentioning

confidence: 99%

Human Immunodeficiency Virus and Atherosclerosis

Farrugia¹,

Lucariello²,

Coppola³

2009

Cardiology in Review

View full text Add to dashboard Cite

The advent of highly active antiretroviral therapy has led to a significant decline in the incidence of mortality and progression to AIDS in HIV-infection. With increased life expectancy, HIV-infected individuals are being affected by cardiovascular disease. Research studies have identified an increased prevalence of traditional coronary risk factors in HIV-infected patients. Additional investigations suggest that the virus itself may independently result in atherosclerosis. Further studies have linked the use of highly active antiretroviral therapy to the atherosclerotic processes. These findings suggest the need to reconsider HIV as one of the traditionally accepted risk factors for coronary artery disease, with treatment aimed at prevention of myocardial infarction.

show abstract

“…Plasma levels of, MIP-1α and MIP-1β were measured during the first 16 weeks of HAART in chronic HIV-1-infected patients. A significant increase was observed in the levels of MIP-1α and MIP-1β in the NNRTI cohort (P = 0.0010 and P = 0.0012, respectively) and a significant decrease in levels of MIP-1α and MIP-1β (P = 0.0015 and P = 0.0299, respectively) was observed over the 16 weeks in the PI cohort [30]. cells observed at week 52 correlated with the degree of antigen exposure [8].…”

Section: Substitution Of Drug Classes and Regimensmentioning

confidence: 75%

Immune Modulation and Reconstitution of HIV-1-Specific Responses: Novel Approaches and Strategies

Burton

Mela²,

Rosignoli³

et al. 2006

CMC

View full text Add to dashboard Cite

Efficacious protection for future generations from HIV-1 infection through the development of prophylactic vaccines is the best hope for the millions of individuals living with the threat of HIV-1 infection. Advances in the development of non-curative chemotherapy for those already infected have changed the course of the epidemic for those with access to the drugs. However in the ten years since the advent of highly active anti-retroviral therapy, the expectancy of curative chemotherapy has been quashed, and the constant need for a next generation of drugs is evident. As our understanding of HIV-1 pathogenesis increases, it is becoming apparent that novel approaches and strategies will be required to halt the global progression of HIV-1. Immune-based therapies are being considered in the context of effective antiretroviral therapy. Such immune-based therapy must allow the induction or regeneration of HIV-1-specific T-cell responses with the potential to control viremia and purge viral reservoirs. Studies of therapy substitution, treatment interruption, therapeutic vaccines and/or cytokines and/or hormones have been carried out and are briefly summarised in this review.

show abstract

Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, β -chemokines and IL-16 secretion in HIV-1 infection

Cited by 10 publications

References 30 publications

Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele

Atherosclerosis in Patients Infected With HIV Is Influenced by a Mutant Monocyte Chemoattractant Protein-1 Allele

Human Immunodeficiency Virus and Atherosclerosis

Immune Modulation and Reconstitution of HIV-1-Specific Responses: Novel Approaches and Strategies

Contact Info

Product

Resources

About